Targeted Oncology Staff

During a live virtual event, Sameer A. Parikh, MBBS, discussed with participating physicians the treatment options for patients with chronic lymphocytic leukemia in the front-line setting by risk assessment.

A 51-year-old man presented with pallor and worsening fatigue on exertion and was diagnosed with multiple myeloma, standard risk, stage II.

Looking at the combination of lenalidomide plus tafasitamab for patients with diffuse large B-cell lymphoma shows promise for patients' treatment, but challenges remain that clinicians need to address.

Tanya Dorff, MD, asks the participants of a roundtable discussion what they would recommend as next-line therapy for a patient with nonmetastatic castration-resistant prostate cancer.

During a Targeted Oncology Case-Based Roundtable event, Melissa L. Johnson, MD, director, discussed the case of 66-year-old man with non–small cell lung cancer.

During a live virtual event with other physicians, Bijal Shah, MD, MS, discussed treatment options for patients with diffuse large B-cell lymphoma and the data that backs up the efficacy for these options.

Tanya Dorff, MD, asks the participants of a roundtable discussion if they would order germline testing and molecular imaging in a patient with nonmetastatic castration-resistant prostate cancer.

A 77-year-old woman presented to her primary care physician with abdominal pain and fatigue.

After 8 months on enzalutamide, a patient with castration-resistant prostate cancer had a PSA level of 60.7 ng/mL. The abdominal/pelvic CT showed enlargement of known pelvic lymph nodes, and a bone scan showed progressive disease.

During a virtual live event with other physicians, Sandy Srinivas, MD, reviewed data for 3 antiandrogens used for patients with nonmetastatic castration-resistant prostate cancer, including apalutamide, darolutamide, and enzalutamide.

In a 73-year-old patient, a PET scan revealed activity in the left upper lobe mass, supraclavicular nodal areas, and liver lesions, and an MRI discovered 1 small asymptomatic brain lesion. This lead to a diagnosis of stage T3N3M1-IV extensive-stage small cell lung cancer.

A 78-year-old woman was diagnosed with stage II multiple myeloma and was deemed transplant ineligible.

Eight months after completion of adjuvant therapy for triple-negative breast cancer, a 48-year-old patient reported worsening fatigue.

A 59-year-old man with a history of smoking, hypertension, and osteoarthritis presented with chest pain, cough, and dyspnea.

A 51-year-old man who presented with pallor and worsening fatigue on exertion was diagnosed with standard risk, stage II multiple myeloma.

A 75-year-old man presented with intermittent right hip pain. The case was discussed between of physicians and moderated by Nauman Moazzam, MD.

A 59-year-old White man presented with chest pain, cough, and dyspnea. The patient was diagnosed with poorly differentiated adenocarcinoma of the lung.

In a patient case reviewed by Gilberto De Lima Lopes, MD, a 59-year-old man presented with chest pain, cough, and dyspnea.

Eleven months after completion of therapy with the R-CHOP regimen, a 43-year-old woman with diffuse large B-cell lymphoma complained of fever, night sweats, and back pain.

A 77-year-old woman presented to her primary care physician complaining of abdominal pain and fatigue. Ghassan K. Abou-Alfa, MD, discussed the case with a group of physicians.

In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, discusses PSA doubling time and participant experience with androgen receptor inhibitors in castration-resistant prostate cancer.

A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 1. He eventually received a diagnosis of stage II standard-risk multiple myeloma after testing and examination.

A patient with metastatic castration-resistant prostate cancer received external beam radiation therapy and androgen deprivation therapy became asymptomatic, then presented with hip pain and urinary frequency 6 months later.

During separate virtual live events, Matthew A. Gubens, MD, MS, and Rodolfo Bordoni, MD, discussed the CASPIAN trial of durvalumab plus platinum therapy and etoposide and whether the participants have used this regimen in patients with small cell lung cancer.

David I. Quinn, MD, MBBS, PhD and other oncologists, discussed disease management and the option of using an osteoclast-targeting agent for a 75-year-old man with metastatic castration-resistant prostate cancer.

A 51-year-old patient who originally presented with pallor and worsening fatigue on exertion was diagnosed with standard-risk, stage II multiple myeloma.

In a roundtable discussion with multiple participants, Alicia K. Morgans, MD, MPH, reviews the options for a patient with castration-resistant prostate cancer who progressed on front-line therapy.

Jeffrey A. Sosman, MD leads a discussion about a 59-year-old Black who woman received a diagnosis of clear cell renal cell carcinoma.

Komal Jhaveri, MD, discussed the case of a 63-year-old patient with HER2-positive metastatic breast cancer during a Targeted Oncology Case-Base Roundtable event.

Molecular testing for a patient with lung cancer revealed a RET fusion and PD-L1 expression of 80%.